Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey

Erdem H. A. , Korkmaz Ekren P. , ÇaĞlayan D., TaŞbakan M., Yamazhan T. , TaŞbakan M. S. , ...More

Turkish journal of medical sciences, vol.51, no.3, pp.912-920, 2021 (Journal Indexed in SCI Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 51 Issue: 3
  • Publication Date: 2021
  • Doi Number: 10.3906/sag-2008-33
  • Title of Journal : Turkish journal of medical sciences
  • Page Numbers: pp.912-920
  • Keywords: SARS-CoV-2, favipiravir, COVID-19, coronavirus, pandemic, antiviral therapy, CORONAVIRUS, INFECTION


Background/aim: The aim of this descriptive article is to share the experience in Ege University, Turkey with favipiravir in the treatment of severe SARS-CoV-2 pneumonia. Materials and methods: This retrospective descriptive study included patients diagnosed with COVID-19 who presented with or developed severe pneumonia. Results: Forty patients who completed a full course (at least 5 days) of favipiravir were included in the study. At baseline, 30 (75%) patients required treatment for respiratory distress. Thirty-three patients (82.5%) were discharged from the hospital with full recovery, 6 patients (15%) died and 1 case (2.5%) was still at the intensive care unit (ICU) when this paper was written. Conclusion: This study provides relevant information for the treatment of COVID-19, suggesting that favipiravir was associated with significant clinical and laboratory improvements in the majority of the patients, is a safe drug with no serious side effects and would merit further investigation.